18 recruiting, 9 completed, 3 active not recruiting, 3 terminated. 21 Phase 1, 21 Phase 2, 3 Phase 3.
Follow Stemline Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer Biospecimen Collection, Computed Tomography, Elacestrant - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 50 | 2026-12-18 | 2026-06-09 |
| KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies MEN2312 - Hematological Malignancy | Phase 1 / Phase 2 | Not yet recruiting | Stemline Therapeutics, Inc. | 115 | 2026-10-30 | 2026-10-14 |
| A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer Elacestrant - Breast Cancer | Phase 2 | Recruiting | Stemline Therapeutics, Inc. | 70 | 2026-08-18 | 2026-10-13 |
| Ph 2 Elacestrant in ER Positive Uterine Sarcomas Elacestrant - Uterine Sarcoma, Uterine Leiomyosarcoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 30 | 2026-03-25 | 2026-05-22 |
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax Tagraxofusp, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukaemia (AML), Leukemia | Phase 1 / Phase 2 | Recruiting | Jacqueline Garcia, MD | 31 | 2026-02-02 | 2026-02-05 |
| PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) Capecitabine, Elacestrant - Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Kristina A. Fanucci | 297 | 2026-01-16 | 2026-08-26 |
| A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer MEN2501 - Platinum-resistant Ovarian Cancer | Phase 1 | Recruiting | Stemline Therapeutics, Inc. | 100 | 2026-01-10 | 2026-07-06 |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients Venetoclax, Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2025-12-11 | 2026-07-01 |
| ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | Kristina A. Fanucci | 65 | 2025-11-17 | 2026-06-10 |
| A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy Chemotherapy - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Recruiting | Stemline Therapeutics, Inc. | 140 | 2025-10-17 | 2026-09-15 | |
| Circulating Tumor DNA Elacestrant - ER+ Breast Cancer | Phase 2 | Recruiting | Yale University | 50 | 2025-09-30 | 2026-09-21 |
| Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML Tagraxofusp, Cladribine (CLAD), Cytarabine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Stanford University | 20 | 2025-02-10 | 2026-04-14 |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy Tagraxofusp, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Stemline Therapeutics, Inc. | 85 | 2025-01-14 | 2026-08-06 |
| Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Olaparib + Elacestrant, Olaparib - Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 2 | Recruiting | GBG Forschungs GmbH | 176 | 2024-12-13 | 2025-12-01 |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Everolimus, Elacestrant, Placebo - Advanced Breast Cancer, ER-positive Breast Cancer | Phase 3 | Recruiting | MedSIR | 300 | 2024-12-05 | 2026-08-24 |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer MEN2312, Elacestrant - Advanced Breast Cancer | Phase 1 | Recruiting | Stemline Therapeutics, Inc. | 240 | 2024-10-25 | 2026-08-07 |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence Elacestrant, Anastrozole, Letrozole - Breast Cancer | Phase 3 | Recruiting | Stemline Therapeutics, Inc. | 4220 | 2024-09-27 | 2026-09-15 |
| Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia Azacitidine, Tagraxofusp-erzs - Acute Myeloid Leukemia | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-08-03 | 2024-03-08 | |
| A Registry-study of ELZONRIS in Participants With BPDCN Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Recruiting | Stemline Therapeutics, Inc. | 80 | 2024-06-26 | 2026-08-25 | |
| Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents Tagraxofusp, Azacitidine, Venetoclax - Acute Myeloid Leukemia | Phase 2 | Recruiting | Joshua Zeidner | 53 | 2024-05-01 | 2026-07-10 |
Showing 20 of 36. Sign in to see all of them.
Breast Neoplasms (11) · Leukemia, Myeloid, Acute (9) · Blastic Plasmacytoid Dendritic Cell Neoplasm (5) · Hematologic Neoplasms (2) · Adenosarcoma of the uterus (1) · Brain Diseases (1) · Brain Neoplasms (1) · Breast Diseases (1) · Breast Neoplasms, Male (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Endometrial Neoplasms (1) · Glioblastoma (1) · Leukemia (1) · Leukemia, Myelomonocytic, Chronic (1)
elacestrant (16) · tagraxofusp (12) · RAD1901 (9) · Azacitidine (5) · venetoclax (5) · Everolimus (3) · Anastrozole (2) · Letrozole (2) · abemaciclib (2) · exemestane (2) · Alpelisib (1) · Bevacizumab (1) · Capecitabine (1) · Carboxymethylcellulose Sodium (1) · Cladribine (1)
United States (27) · Spain (8) · France (7) · Italy (7) · United Kingdom (7) · Germany (6) · Australia (5) · Belgium (5) · Austria (4) · Brazil (4) · Greece (4) · South Korea (4) · Argentina (3) · Canada (3) · Denmark (3)
Kristina Fanucci, MD (2) · Andrew Lane, MD, PhD (1) · Antonio Llombart-Cussac, M.D., Ph.D. (1) · Caspian Oliai, MD (1) · Elisabeth GE de Vries, MD (1) · Jacqueline Garcia, MD (1) · Jordyn Silverstein, MD (1) · Joshua Zeidner, MD (1) · Mariya Rozenblit, MD (1) · Sibylle Loibl, MD, PhD (1) · Suzanne George, MD (1)
PMID 31018069, PMID 31426673, PMID 32912274, PMID 33513026, PMID 33795208, PMID 35584336, PMID 35820082, PMID 38052038, PMID 38381994, PMID 40919483, PMID 41146971, PMID 41486505
2015 (1)